In One aspect, the Disclosure provides methods to control the profiles pharmacokinetic (PK) and / or pharmacodynamic (PD) of insulin in a manner that is sensitive to the systemic concentrations of a saccharide such as Glucose.As discussed in the examples, it was discovered that when insulin was conjugated with carbohydrate ligands Exhibit High affinity, PK / PD Profiles could be made to respond to changes sacarida concentration even in the absence of a Molecule and the Exogenous jijadora multivalent saccharides such co Mo with.This finding was unexpected and provides an unprecedented opportunity to generate simple Systems of insulin Sensitive Lectin free saccharides. In Another aspect, the Disclosure provides Conjugates and Methods for Manufacturing the same. In general, These include a drug conjugated ligands and one or more separate, each of which includes a saccharide.In certain embodiments, the ligands are able to compete with a saccharide (e.g. glucose or Mannose) to join a Molecule binding endogenous saccharides. In certain embodiments, the ligands are able to compete with glucose or Mannose by Binding with.As explained in more detail below, in certain embodiments, the ligands and the drug can be covalently or non covalently bound to a conjugated structure. In certain embodiments, the polymer structure is not. In certain relalizaciones, the conjugate can have a polydispersity Index one and a Molecular Weight of less than 20000. Gives approximately.In certain embodiments, the conjugate is of Long Duration (i.e., has a pharmacokinetic profile that is more sustained than the recombinant soluble human insulin or RHI).As is discussed in more detail below, it should be understood that the methods and formulations, (as described in this document are not limited in any way, only the delivery of insulin and it should be understood that can be used to free any medicine.It should also understand that the methods can be used to release drugs in response to different sac
